HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.
暂无分享,去创建一个
I. E. Smith | Dennis L. Buckley | C. Crews | N. Darricarrère | J. Harling | K. Raina | J. Hines | J. Gustafson | Afjal H. Miah | Craig M Crews | John D Harling | Dennis L Buckley | John Hines | Afjal H Miah | Jeffrey L Gustafson | Kanak Raina | Nicole Darricarrere | Ian E Smith | Kanak Raina
[1] A. Ransick,et al. Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation* , 2003, Molecular & Cellular Proteomics.
[2] Lisa M. Ryno,et al. Broadly applicable methodology for the rapid and dosable small molecule-mediated regulation of transcription factors in human cells. , 2013, Journal of the American Chemical Society.
[3] W. L. Jorgensen,et al. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. , 2012, Angewandte Chemie.
[4] R. Deshaies,et al. Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] Lisa M. Ryno,et al. Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. , 2013, Cell reports.
[6] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[7] E. Choi,et al. Targeted Degradation of the Aryl Hydrocarbon Receptor by the PROTAC Approach: A Useful Chemical Genetic Tool , 2007, Chembiochem : a European journal of chemical biology.
[8] Yukihiro Itoh,et al. Development of target protein-selective degradation inducer for protein knockdown. , 2011, Bioorganic & medicinal chemistry.
[9] E. Choi,et al. Impact of linker length on the activity of PROTACs. , 2011, Molecular bioSystems.
[10] Thomas B. Sundberg,et al. Identification of Hydrophobic Tags for the Degradation of Stabilized Proteins , 2012, Chembiochem : a European journal of chemical biology.
[11] Scott M Lippman,et al. Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.
[12] T. Aoyagi,et al. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. , 1976, The Journal of antibiotics.
[13] L. Banaszynski,et al. A Rapid, Reversible, and Tunable Method to Regulate Protein Function in Living Cells Using Synthetic Small Molecules , 2006, Cell.
[14] Michael A. Koldobskiy,et al. Chemical genetic control of protein levels: selective in vivo targeted degradation. , 2004, Journal of the American Chemical Society.
[15] R. Deshaies,et al. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer , 2008, Oncogene.
[16] Julien Michel,et al. Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction , 2012, Journal of the American Chemical Society.
[17] K. Sakamoto. Protacs for Treatment of Cancer , 2010, Pediatric Research.
[18] Andreas Thomann,et al. Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. , 2012, Chemistry & biology.
[19] Vishva M Dixit,et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. , 2007, Cell.
[20] Vishva M. Dixit,et al. IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.
[21] Marjeta Urh,et al. HaloTag: a novel protein labeling technology for cell imaging and protein analysis. , 2008, ACS chemical biology.
[22] Yukihiro Itoh,et al. Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist. , 2012, Bioorganic & medicinal chemistry letters.
[23] Junko Yaegashi,et al. Precise control of protein concentration in living cells. , 2010, Angewandte Chemie.
[24] C. Contag,et al. Chemical control of protein stability and function in living mice , 2008, Nature Medicine.
[25] K. Wood,et al. HaloTag7: a genetically engineered tag that enhances bacterial expression of soluble proteins and improves protein purification. , 2009, Protein expression and purification.
[26] T. Corson,et al. Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs , 2013, Proceedings of the National Academy of Sciences.
[27] C. Crews,et al. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. , 2008, Bioorganic & medicinal chemistry letters.
[28] C. Crews,et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[29] L. Banaszynski,et al. Conditional control of protein function , 2006, Chemistry & biology.
[30] Chad J. Miller,et al. A comprehensive mathematical model for three-body binding equilibria. , 2013, Journal of the American Chemical Society.
[31] E. Choi,et al. Two‐Headed PROTAC: An Effective New Tool for Targeted Protein Degradation , 2010, Chembiochem : a European journal of chemical biology.
[32] J. Downward. Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.
[33] T. Corson,et al. Small-Molecule Hydrophobic Tagging Induced Degradation of HaloTag Fusion Proteins , 2011, Nature Chemical Biology.
[34] Corey W. Liu,et al. Small molecule displacement of a cryptic degron causes conditional protein degradation , 2011, Nature chemical biology.
[35] S. Fulda,et al. Targeting IAP proteins for therapeutic intervention in cancer , 2012, Nature Reviews Drug Discovery.
[36] Minoru Ishikawa,et al. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. , 2010, Journal of the American Chemical Society.
[37] Yukihiro Itoh,et al. Specific degradation of CRABP‐II via cIAP1‐mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein , 2011, FEBS letters.
[38] Dennis L. Buckley,et al. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. , 2014, Angewandte Chemie.
[39] C. Crews,et al. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. , 1999, Bioorganic & medicinal chemistry letters.